These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Detection of HLA IgG antibodies by two enzyme-linked immunoassays, solubilized HLA class I and PRA-STAT. Comparison with the AHG PRA. Bryan CF; Baier KA; Flora-Ginter G; Shield CF; Warady BA; Aeder MI; Borkon AM; Estep TH; Forster J; Landreneau MD Transplantation; 1995 Dec; 60(12):1588-94. PubMed ID: 8545895 [TBL] [Abstract][Full Text] [Related]
44. Pretransplant rejection risk assessment through enzyme-linked immunosorbent assay analysis of anti-HLA class I antibodies. Regan J; Monteiro F; Speiser D; Kalil J; Pouletty P; Buelow R Am J Kidney Dis; 1996 Jul; 28(1):92-8. PubMed ID: 8712228 [TBL] [Abstract][Full Text] [Related]
45. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival. ten Hoor GM; Coopmans M; Allebes WA Transplantation; 1993 Aug; 56(2):298-304. PubMed ID: 7689256 [TBL] [Abstract][Full Text] [Related]
46. Transplant rejection associated with the presence of human leucocyte antigen antibodies detected by the Fc gamma R inhibition test but not by the lymphocytotoxicity test. Neppert J; Claas FH; Persijn GG; Washington G; Tapken A Transpl Immunol; 1997 Mar; 5(1):45-8. PubMed ID: 9106334 [TBL] [Abstract][Full Text] [Related]
47. [C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Wahrmann M; Exner M; Haidbauer B; Schillinger M; Regele H; Körmöczi G; Böhmig GA Hum Immunol; 2005 May; 66(5):526-34. PubMed ID: 15935890 [TBL] [Abstract][Full Text] [Related]
48. Detection of HLA-specific antibodies by PRA-STAT and their association with transplant outcome. Worthington JE; Thomas AA; Dyer PA; Martin S Transplantation; 1998 Jan; 65(1):121-5. PubMed ID: 9448156 [TBL] [Abstract][Full Text] [Related]
49. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Kosmoliaptsis V; Bradley JA; Peacock S; Chaudhry AN; Taylor CJ Transplantation; 2009 Mar; 87(6):813-20. PubMed ID: 19300182 [TBL] [Abstract][Full Text] [Related]
50. Typing of a panel of soluble HLA class I antigens by enzyme-linked immunosorbent assay. Pouletty C; Mercier I; Glanville L; Tomavo N; Igoudin L; Pouletty P; Buelow R Hum Immunol; 1994 Jul; 40(3):218-27. PubMed ID: 7960966 [TBL] [Abstract][Full Text] [Related]
51. The ABCs (DRDQDPs) of the prozone effect in single antigen bead HLA antibody testing: Lessons from our highly sensitized patients. Greenshields AL; Liwski RS Hum Immunol; 2019 Jul; 80(7):478-486. PubMed ID: 31080010 [TBL] [Abstract][Full Text] [Related]
52. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Monteiro F; Buelow R; Mineiro C; Rodrigues H; Kalil J Transplantation; 1997 Feb; 63(4):542-6. PubMed ID: 9047148 [TBL] [Abstract][Full Text] [Related]
53. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Visentin J; Guidicelli G; Bachelet T; Jacquelinet C; Audry B; Nong T; Dubois V; Moreau JF; Lee JH; Couzi L; Merville P; Taupin JL Transplantation; 2014 Oct; 98(7):738-44. PubMed ID: 25289917 [TBL] [Abstract][Full Text] [Related]
54. Getting on target: Development of the novel, prozone-resistant, dual antibody rapid test (DART) for the LABScreen single antigen bead (SAB) assay. Greenshields A; Bray RA; Gebel HM; Liwski RS Hum Immunol; 2019 Jul; 80(7):468-477. PubMed ID: 31040048 [TBL] [Abstract][Full Text] [Related]
55. Improved flow cytometry based cytotoxicity and binding assay for clinical antibody HLA crossmatching. Alheim M; Paul PK; Hauzenberger DM; Wikström AC Hum Immunol; 2015 Nov; 76(11):849-57. PubMed ID: 26429307 [TBL] [Abstract][Full Text] [Related]
56. Determination of acceptable HLA mismatches in highly sensitized patients by soluble HLA class I ELISA inhibition. Koelman CA; van Beelen E; Witvliet MD; Doxiadis II; Claas FH Transplantation; 2000 Feb; 69(4):656-60. PubMed ID: 10708125 [TBL] [Abstract][Full Text] [Related]
57. Comparison of crossmatch results obtained by ELISA, flow cytometry, and conventional methodologies. Pelletier RP; Adams PW; Hennessy PK; Orosz CG Hum Immunol; 1999 Sep; 60(9):855-61. PubMed ID: 10527393 [TBL] [Abstract][Full Text] [Related]
58. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Kerman RH; Susskind B; Buelow R; Regan J; Pouletty P; Williams J; Gerolami K; Kerman DH; Katz SM; Van Buren CT; Kahan BD Transplantation; 1996 Jul; 62(2):201-5. PubMed ID: 8755816 [TBL] [Abstract][Full Text] [Related]
59. Antibody screening by enzyme-linked immunosorbent assay using pooled soluble HLA in renal transplant candidates. Zaer F; Metz S; Scornik JC Transplantation; 1997 Jan; 63(1):48-51. PubMed ID: 9000659 [TBL] [Abstract][Full Text] [Related]
60. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Schönemann C; Groth J; Leverenz S; May G Transplantation; 1998 Jun; 65(11):1519-23. PubMed ID: 9645818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]